NO126735B - - Google Patents
Download PDFInfo
- Publication number
- NO126735B NO126735B NO00161168A NO16116866A NO126735B NO 126735 B NO126735 B NO 126735B NO 00161168 A NO00161168 A NO 00161168A NO 16116866 A NO16116866 A NO 16116866A NO 126735 B NO126735 B NO 126735B
- Authority
- NO
- Norway
- Prior art keywords
- chlorine
- group
- diazepine
- stands
- dihydro
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 47
- 229910052801 chlorine Inorganic materials 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 23
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 16
- 239000000460 chlorine Substances 0.000 claims description 15
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims description 11
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 229940053197 benzodiazepine derivative antiepileptics Drugs 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 48
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- 239000013078 crystal Substances 0.000 description 29
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- 238000000354 decomposition reaction Methods 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 description 11
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- IXZDIALLLMRYOU-UHFFFAOYSA-N tert-butyl hypochlorite Chemical compound CC(C)(C)OCl IXZDIALLLMRYOU-UHFFFAOYSA-N 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 238000012360 testing method Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000005708 Sodium hypochlorite Substances 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 230000008707 rearrangement Effects 0.000 description 7
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 238000001953 recrystallisation Methods 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 235000010418 carrageenan Nutrition 0.000 description 5
- 229920001525 carrageenan Polymers 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 230000001773 anti-convulsant effect Effects 0.000 description 4
- 239000000679 carrageenan Substances 0.000 description 4
- 229940113118 carrageenan Drugs 0.000 description 4
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 3
- 210000004100 adrenal gland Anatomy 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000005660 chlorination reaction Methods 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 240000001624 Espostoa lanata Species 0.000 description 2
- 235000009161 Espostoa lanata Nutrition 0.000 description 2
- 206010018691 Granuloma Diseases 0.000 description 2
- 238000007126 N-alkylation reaction Methods 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 2
- 229910052808 lithium carbonate Inorganic materials 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 239000003158 myorelaxant agent Substances 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical class C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- LGDAGYXJBDILKZ-UHFFFAOYSA-N [2-methyl-1,1-dioxo-3-(pyridin-2-ylcarbamoyl)-1$l^{6},2-benzothiazin-4-yl] 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 LGDAGYXJBDILKZ-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000001804 chlorine Chemical class 0.000 description 1
- 229920005556 chlorobutyl Polymers 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- WDCDAAMJNUHOIY-UHFFFAOYSA-N ethyl acetate;2-propan-2-yloxypropane Chemical compound CCOC(C)=O.CC(C)OC(C)C WDCDAAMJNUHOIY-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- -1 lithium halide Chemical class 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000001670 myorelaxant effect Effects 0.000 description 1
- 230000010925 negative regulation of granuloma formation Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- MZQCFPABNHFYAT-UHFFFAOYSA-M sodium;propan-2-one;iodide Chemical compound [Na+].[I-].CC(C)=O MZQCFPABNHFYAT-UHFFFAOYSA-M 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 210000003699 striated muscle Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000007738 vacuum evaporation Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1391A FR1455048A (fr) | 1965-01-09 | 1965-01-09 | Composés de la série des benzodiazépines et leur préparation |
| FR12687A FR4429M (xx) | 1965-01-09 | 1966-09-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO126735B true NO126735B (xx) | 1973-03-19 |
Family
ID=26161511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO00161168A NO126735B (xx) | 1965-01-09 | 1966-01-07 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US3426014A (xx) |
| JP (1) | JPS4913798B1 (xx) |
| AT (1) | AT280291B (xx) |
| BE (1) | BE674833A (xx) |
| BR (1) | BR6676281D0 (xx) |
| CH (1) | CH471137A (xx) |
| DE (3) | DE1670621A1 (xx) |
| FI (1) | FI47987C (xx) |
| FR (2) | FR1455048A (xx) |
| GB (2) | GB1135781A (xx) |
| IL (1) | IL24875A (xx) |
| NL (2) | NL6600095A (xx) |
| NO (1) | NO126735B (xx) |
| SE (1) | SE343583B (xx) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0015904D0 (en) | 2000-06-28 | 2000-08-23 | Hoffmann La Roche | Inhibitors of HPV E1 helicase enzyme |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3268586A (en) * | 1966-08-23 | Armnophenyl cycloalkyl ketones | ||
| US3179656A (en) * | 1965-04-20 | Azepine x-oxidss | ||
| FR1391752A (fr) * | 1963-11-15 | 1965-02-01 | Clin Byla Ets | Mino cétones de la série aromatique, leurs dérivés et la préparation de ces divers produits. |
-
1965
- 1965-01-09 FR FR1391A patent/FR1455048A/fr not_active Expired
- 1965-12-27 IL IL24875A patent/IL24875A/xx unknown
- 1965-12-29 US US517434A patent/US3426014A/en not_active Expired - Lifetime
-
1966
- 1966-01-04 FI FI660014A patent/FI47987C/fi active
- 1966-01-05 DE DE19661670621 patent/DE1670621A1/de active Pending
- 1966-01-05 NL NL6600095A patent/NL6600095A/xx unknown
- 1966-01-05 DE DE1670620A patent/DE1670620C3/de not_active Expired
- 1966-01-05 DE DE1670595A patent/DE1670595C3/de not_active Expired
- 1966-01-07 BE BE674833D patent/BE674833A/xx unknown
- 1966-01-07 GB GB945/66A patent/GB1135781A/en not_active Expired
- 1966-01-07 SE SE205/66A patent/SE343583B/xx unknown
- 1966-01-07 NO NO00161168A patent/NO126735B/no unknown
- 1966-01-07 BR BR176281/66A patent/BR6676281D0/pt unknown
- 1966-01-07 AT AT11688/67A patent/AT280291B/de not_active IP Right Cessation
- 1966-01-07 CH CH21766A patent/CH471137A/fr not_active IP Right Cessation
- 1966-01-07 GB GB30329/68A patent/GB1135782A/en not_active Expired
- 1966-01-09 JP JP41000904A patent/JPS4913798B1/ja active Pending
- 1966-09-19 FR FR12687A patent/FR4429M/fr not_active Expired
-
1973
- 1973-08-03 NL NL7310780A patent/NL7310780A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR6676281D0 (pt) | 1973-09-06 |
| DE1670620B2 (de) | 1973-03-01 |
| DE1670595C3 (de) | 1978-11-30 |
| FI47987B (xx) | 1974-01-31 |
| GB1135782A (en) | 1968-12-04 |
| US3426014A (en) | 1969-02-04 |
| DE1670620A1 (de) | 1969-10-16 |
| DE1670621A1 (de) | 1971-07-22 |
| GB1135781A (en) | 1968-12-04 |
| FR1455048A (fr) | 1966-04-01 |
| FR4429M (xx) | 1966-09-19 |
| FI47987C (fi) | 1974-05-10 |
| CH471137A (fr) | 1969-04-15 |
| SE343583B (xx) | 1972-03-13 |
| DE1670595B2 (de) | 1978-04-06 |
| DE1670620C3 (de) | 1973-10-04 |
| JPS4913798B1 (xx) | 1974-04-03 |
| AT280291B (de) | 1970-04-10 |
| NL6600095A (xx) | 1966-07-11 |
| IL24875A (en) | 1970-01-29 |
| NL7310780A (xx) | 1973-10-25 |
| BE674833A (xx) | 1966-07-07 |
| DE1670595A1 (de) | 1970-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2206012A1 (de) | Pharmazeutisches Präparat | |
| DE1545933A1 (de) | Verfahren zur Herstellung von Benzodiazepin-Derivaten | |
| CH630381A5 (de) | Verfahren zur herstellung von diazepinderivaten. | |
| DE1545952A1 (de) | Verfahren zur Herstellung von Benzodiazepin-Derivaten | |
| DE2323149B2 (de) | Thienopyrimidine, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneipräparate | |
| NO126325B (xx) | ||
| DE2810476A1 (de) | Benzodiazepin-derivate, verfahren zu ihrer herstellung und solche derivate enthaltende arzneimittel | |
| NO126735B (xx) | ||
| DE2508543A1 (de) | Verfahren zur herstellung von imidazo- und pyrimido eckige klammer auf 2,1-b eckige klammer zu -chinazolinen und neue chinazoline | |
| DE2041868A1 (de) | Verfahren zur Herstellung neuer heterocyclischer Verbindungen | |
| NO117366B (xx) | ||
| DE1955349C2 (de) | s-Triazolo [4,3-a] [1,4] benzodiazepine | |
| DE2220739A1 (de) | Neue in 1-Stellung substituierte 6-Phenyl-4H-s-triazolo [4,3-a][1,4] benzodiazepine und Verfahren zu ihrer Herstellung | |
| Huckle et al. | 4-Amino-2, 3, 4, 5-tetrahydro-1-benzoxepin-5-ols, 4-amino-2, 3, 4, 5-tetrahydro-1-benzothiepin-5-ols, and related compounds | |
| NO771560L (no) | Fremgangsm}te for fremstilling av benzodiazepin-derivater | |
| US2904554A (en) | Phthalides | |
| EP0072029B1 (de) | Triazolobenzazepine, Verfahren und Zwischenprodukte zu deren Herstellung und diese enthaltende Arzneimittel | |
| DE2439209A1 (de) | Neue 6-phenyl-s-triazolo eckige klammer auf 4,3-a eckige klammer zu eckige klammer auf 1,3,4 eckige klammer zu benzotriazepine | |
| US3966756A (en) | Substituted dibenzo[b,f]tetrazolo[1,5-d][1,4]-oxazepines | |
| AT395155B (de) | Verfahren zur herstellung von neuen imidazo(1,5-a)(1,4)diazepinverbindungen | |
| US3300482A (en) | Certain pyridobenzodiazepine derivatives | |
| DE2448259A1 (de) | Verfahren zur herstellung von 2-halogenmethyl-1,4-benzodiazepinen | |
| DE2813734A1 (de) | Pyrazolo eckige klammer auf 1,5-a eckige klammer zu pyrido eckige klammer auf 2,3-d eckige klammer zu pyrimidin-9 (4h)-on-derivate | |
| AT266144B (de) | Verfahren zur Herstellung von Benzodiazepin-Derivaten | |
| NO792319L (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive triazolo-tieno-diazepiner |